title: Synergistic Effect of the Combination of Novel Suberoylanilide Hydroxamic Acid Derivatives with Cisplatin on Anti-proliferation of Human Cancer Cells.
abstract: A novel, green, and atom-economical boric acid catalyzed direct amidation without the use of any coupling agents for the preparation of suberoylanilide hydroxamic acid (SAHA) and SAHA-based inhibitors targeting anti-proliferation of cancer cells is provided. The new SAHA-based inhibitor B123, when used alone, exhibited higher anti-proliferative activities than SAHA or Cisplatin against a number of human cancer cells. We have examined the effect of combination of these SAHA-based inhibitors with Cisplatin. We found synergistic effects of the combination of SAHA-based inhibitors with Cisplatin over a wide range of concentrations against human liver cancer cells HepG2 and two human lung cancer cell lines H1299 and H460. This synergism leads up to 8-fold of dose reduction for Cisplatin in the combination with our synthesized inhibitor B123 against H1299.
authors.forename: Rui
authors.initials: R
authors.lastname: Xie
authors.forename: Jinghua
authors.initials: J
authors.lastname: Shi
authors.forename: Chunhui
authors.initials: C
authors.lastname: Cheng
authors.forename: Fan
authors.initials: F
authors.lastname: Yun
authors.forename: Xia
authors.initials: X
authors.lastname: Liu
authors.forename: Pingwah
authors.initials: P
authors.lastname: Tang
authors.forename: Xinying
authors.initials: X
authors.lastname: Wu
authors.forename: Ming
authors.initials: M
authors.lastname: Yang
authors.affiliation: College of Life Science and Technology, Beijing University of Chemical Technology, Beijing 100029, China. yuanqp@mail.buct.edu.cn.
authors.forename: Qipeng
authors.initials: Q
authors.lastname: Yuan
mesh_terms: D000813:Anilides / Q000008:administration & dosage / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology*; D004354:Drug Screening Assays, Antitumor; D004357:Drug Synergism; D055772:Green Chemistry Technology; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D000813:Anilides; D000970:Antineoplastic Agents; C000621013:B113 compound; C000621014:B123 compound; D006877:Hydroxamic Acids; D002945:Cisplatin